EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer

Pedro Antunes Meireles iD, Sofia Fragoso iD, Teresa Duarte, Sidónia Santos, Catarina Bexiga, Priscila Nejo, Ana Luís, Beatriz Mira, Isália Miguel, Paula Rodrigues, Fátima Vaz

Cancers · 03.12.2023 · 15 (23) · 5699

DOI: 10.3390/cancers15235699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 03.12.2023. Verfasst von Pedro Antunes Meireles und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Germline pathogenic variants (PV) in BRCA1 and BRCA2 genes, which account for 20% of familial breast cancer (BC) cases, are highly penetrant and are associated with Hereditary Breast/Ovarian Cancer Syndrome. Previous studies, mostly including higher numbers of BRCA1 BC patients, yielded conflicting results regarding BRCA1/2 BC outcomes. In the Portuguese population, BRCA2 BC is diagnosed more frequently than BRCA1 BC. We aimed to compare clinicopathological characteristics and prognosis between BC patients with BRCA1 and BRCA2 mutations and a control group without germline PV (BRCA-wt). Furthermore, we explored the frequency and outcomes of risk-reducing surgeries in BRCA-mutated patients.

Methods

Prospective follow-up was proposed for patients with a diagnosed BRCA1/2 PV. For this study, a matched control group (by age at diagnosis, by decade, and by stage at diagnosis) included BC patients without germline PV. We compared overall survival (OS) and invasive disease-free survival (iDFS) within the three groups, and the use of risk-reducing surgeries among the BRCA cohort.

Results

For a mean follow-up time of 113.0 months, BRCA-wt patients showed longer time to recurrence (p = 0.002) and longer OS (p < 0.001). Among patients with BRCA mutations, no statistical differences were found, although patients with BRCA2 BC had longer iDFS and OS. Uptake of risk-reducing surgeries (contralateral prophylactic mastectomy and salpingo-oophorectomy) were negative predictors of invasive disease and death, respectively.

Conclusions

Testing positive for a BRCA PV is associated with a higher risk of relapse and death in patients with BC in the Portuguese population. Risk-reducing mastectomy and salpingo-oophorectomy were associated with lower incidence of relapse and longer median iDFS and OS, respectively.

Schlagwörter

Stichwörter der Autor:innen

BRCA1BRCA2breast cancerhereditary breast cancerprognosisrisk-reducing surgeries

Autor:innen und Institutionen

  • Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.
  • Molecular Pathobiology Research Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.
  • Familial Cancer Clinic Unit, Instituto Português de Oncologia de Lisboa Francisco Gentil, 1099-023 Lisbon, Portugal.

ORCID-Profile: Pedro Antunes Meireles, Sofia Fragoso

Zitieren

APA

Antunes Meireles, P., Fragoso, S., Duarte, T., Santos, S., Bexiga, C., Nejo, P., Luís, A., Mira, B., Miguel, I., Rodrigues, P., & Vaz, F. (2023). Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer. Cancers, 15(23), 5699. https://doi.org/10.3390/cancers15235699

Vancouver

Antunes Meireles P, Fragoso S, Duarte T, Santos S, Bexiga C, Nejo P, et al. Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer. Cancers. 2023;15(23):5699. doi:10.3390/cancers15235699

BibTeX
@article{AntunesMeireles2023,
  author = {Antunes Meireles, Pedro and Fragoso, Sofia and Duarte, Teresa and Santos, Sidónia and Bexiga, Catarina and Nejo, Priscila and Luís, Ana and Mira, Beatriz and Miguel, Isália and Rodrigues, Paula and Vaz, Fátima},
  title = {Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {23},
  pages = {5699},
  doi = {10.3390/cancers15235699}
}
Kostenlos starten →